Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Depomed and Watson Pharmaceuticals have entered into a co-promotion agreement for ProQuin XR, Depomed's extended release formulation of ciprofloxacin hydrochloride for the treatment of uncomplicated urinary tract infections.
Subscribe to our email newsletter
Under the agreement, Depomed has granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care specialties in the US and its possessions, including Puerto Rico.
Pursuant to the agreement, Depomed will book top-line revenue and Watson will receive a portion of the profits. Watson and Depomed plan to re-launch ProQuin XR in the US urology market by the end of this year. Depomed retains manufacturing and distribution rights and Watson will be responsible for promotion to physicians in urology and long-term care.